Key Points
- Nationwide recall issued;
- Siberia and ZYN affected;
- Unauthorized sales cited;
- All lots impacted;
- Classified as Type II recall.
2Firsts
June 15, 2026
Health Canada has issued a nationwide recall affecting nicotine pouch products sold under the Siberia and ZYN brands, citing unauthorized sales in the Canadian market.
According to the recall notice, the affected Siberia products are 35 mg nicotine pouches in Super Slim, White Dry, Power White and White Slim varieties. All lots are included in the recall.
The recall also covers ZYN 6 mg nicotine pouch products in Cool Mint, Wintergreen, Spearmint, Menthol, Chill and Peppermint varieties, with all lots affected.
Brand | Nicotine Strength | Affected Flavours / Types | Lots Affected | Reason for Recall & Potential Risks |
ZYN | 6 mg | Cool Mint, Wintergreen, Spearmint, Menthol, Chill, Peppermint | All lots | Reason: Sold without market authorization (Drug Identification Number - DIN) from Health Canada. Risks: Categorized as a Type II recall (the probability of serious adverse health consequences is remote). However, without regulatory oversight, there is no guarantee regarding ingredients, safety, or labeling compliance. |
Siberia | 35 mg (Extremely High) | Super slim, white dry, power white, white slim | All lots | Reason: Sold without market authorization (DIN) in Canada. Risks: 35 mg represents an extremely high nicotine concentration. Unauthorized high-dose nicotine products pose severe risks of acute poisoning, leading to symptoms like rapid heart rate, severe nausea, dizziness, or respiratory issues. |
Health Canada said the recall was not triggered by a product-quality defect but because the products were being sold without market authorization in Canada.
The agency classified the action as a Type II recall. Under Health Canada’s classification system, a Type II recall involves products whose use or exposure may cause temporary adverse health consequences, while the probability of serious adverse health effects is considered remote.
Consumers are advised to verify whether they possess affected products.
For individuals currently using the products, Health Canada recommends consulting a healthcare provider before discontinuing use, particularly for regular users or those with nicotine dependence.
Consumers with questions are encouraged to contact the recalling company directly.
The agency also called on consumers to report adverse reactions, health incidents and product safety concerns associated with the recalled products.
The recall is notable because ZYN has become one of the fastest-growing modern oral nicotine brands globally. Its parent company, Philip Morris International (PMI), has continued expanding the product’s presence across the United States and other international markets.
Canada currently permits the sale of nicotine pouch products only if they have received appropriate regulatory authorization. Since 2024, the federal government has tightened controls on nicotine pouches, requiring approved products to be sold primarily through pharmacies while introducing stricter labeling, advertising and flavor restrictions.
Industry observers say the recall underscores continued regulatory scrutiny of unauthorized nicotine products in Canada and highlights how governments are strengthening market-access and compliance requirements as the nicotine pouch category expands globally.
Cover image: 604 Now
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
